查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1541100

2024-2032 年按药物类别、适应症、最终用户和地区分類的青光眼治疗市场报告

Glaucoma Therapeutics Market Report by Drug Class, Indication, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球青光眼治疗市场规模达79亿美元。青光眼在全球范围内的盛行率不断上升、早期检测诊断技术的不断进步、眼科远距医疗的日益普及以及外科手术中的众多技术创新是推动市场发展的一些因素。

青光眼治疗市场分析：

市场成长与规模：全球青光眼治疗市场正在经历适度成长，其推动因素包括全球青光眼盛行率不断上升以及易患这种眼疾的老化人口不断增加。

主要市场驱动因素：主要驱动因素包括个人对早期诊断和治疗重要性的认识不断提高。

主要市场趋势：联合疗法的采用和新型药物输送系统的开发出现了显着的转变，这有望彻底改变青光眼的治疗。这些趋势是由对更有效的治疗方案和提高患者依从性的需求所推动的。

地理趋势：由于高额医疗支出、完善的医疗基础设施以及对青光眼的认识提高，北美在市场上占据主导地位。然而，由于医疗保健投资的增加和医疗保健设施的改善，亚太地区正在成为一个快速成长的市场。

竞争格局：市场竞争适度，多家全球企业占据主导地位。这些公司从事研发 (R&D) 活动、策略联盟和併购 (M&A)，以巩固其市场地位并扩大其产品组合。

挑战与机会：挑战包括严格的监管架构、高昂的治疗成本以及欠发达地区缺乏认知。儘管如此，市场参与者创新和差异化其产品的机会预计将克服这些挑战。

青光眼治疗市场趋势/驱动因素：

手术过程中的众多技术创新

外科手术技术创新的出现对全球市场产生了重大影响。最具突破性的进展之一是微创青光眼手术（MIGS）。事实证明，这些手术干预措施具有变革性，因为与小梁切除术等传统手术方法相比，併发症更少，恢復时间更短，并且更容易实施。 MIGS 的简单性为外科医生提供了更多选择来有效管理疾病，同时最大限度地减少患者的潜在风险和不适。此外，微型支架和新型引流系统等外科医疗器材的进步进一步提高了青光眼手术的效果。这些进步反过来又增加了全球医疗保健从业者和患者对手术解决方案作为青光眼可行治疗选择的信任。

眼科远距医疗的采用率不断上升

远距医疗已日益成为医疗保健不可或缺的一部分，当涉及青光眼治疗市场时，其在眼科的应用尤其值得关注。医疗数位化，加上软硬体技术的进步，使得远距会诊变得实用且有效。现在患者可以监测自己的病情，而无需频繁去医院，这对于居住在农村或偏远地区的患者尤其有利。医疗保健服务范围的扩大提高了患者的参与度，从而有助于取得更好的结果。远距会诊可以实现持续监控，即时资料可以提醒医疗保健提供者註意患者病情的变化，可能需要立即干预。增强的资料收集能力也为研究提供了前所未有的机会，从而有可能加速新治疗方式的发展。

更重视病人照护的整体方法

综合的整体治疗计划通常涉及多学科的医疗保健提供者团队，包括营养师、物理治疗师和心理咨商师等。这不仅为患者提供了更全面的治疗计划，而且还开启了医疗保健生态系统内的交叉销售和追加销售机会。重点已经从治疗症状转向更全面的方法，同时考虑患者教育、生活方式的改变和预防措施以及医疗干预措施。整体方法也认识到饮食、运动和压力管理等生活方式因素在治疗青光眼中的作用。对患者进行有关有助于降低眼内压的食物类型和活动的教育，眼内压是青光眼的关键因素。这种多管齐下的方法不仅提高了医疗效果，而且改善了患者的整体生活品质。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球青光眼治疗市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依药物类别

  • 前列腺素类似物
    • 市场趋势
    • 市场预测
  • β受体阻断剂
    • 市场趋势
    • 市场预测
  • α肾上腺素激动剂
    • 市场趋势
    • 市场预测
  • 碳酸酐酶抑制剂
    • 市场趋势
    • 市场预测
  • 复方药物
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依迹象

  • 开角型青光眼
    • 市场趋势
    • 市场预测
  • 闭角型青光眼
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：依最终用户

  • 医院
    • 市场趋势
    • 市场预测
  • 眼科诊所
    • 市场趋势
    • 市场预测
  • 门诊手术中心
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Aerie Pharmaceuticals Inc.
    • Allergan Plc
    • Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
    • Inotek Pharmaceuticals Corp.
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Santen Pharmaceutical Co. Ltd.
    • SIFI SpA
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112024A2770

The global glaucoma therapeutics market size reached US$ 7.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.2 Billion by 2032, exhibiting a growth rate (CAGR) of 5.6% during 2024-2032. The growing prevalence of glaucoma across the globe, continual advancements in diagnostic technologies for early detection, the rising adoption of telemedicine in ophthalmology, and numerous technological innovations in surgical procedures represent some of the factors that are propelling the market.

Glaucoma Therapeutics Market Analysis:

Market Growth and Size: The global glaucoma therapeutics market is experiencing moderate growth, driven by factors like the increasing prevalence of glaucoma globally and a rising aging population susceptible to this eye condition.

Major Market Drivers: Key drivers include the growing awareness among individuals about the importance of early diagnosis and treatment.

Key Market Trends: There is a notable shift towards the adoption of combination therapies and the development of novel drug delivery systems, which are poised to revolutionize glaucoma management. These trends are driven by the need for more effective treatment regimens and improved patient compliance.

Geographical Trends: North America dominates the market, driven by high healthcare expenditure, a well-established healthcare infrastructure, and heightened awareness about glaucoma. However, Asia Pacific is emerging as a fast-growing market on account of the increasing healthcare investments and improving healthcare facilities.

Competitive Landscape: The market is moderately competitive, with several global players dominating the scene. These companies are engaged in research and development (R&D) activities, strategic alliances, and mergers and acquisitions (M&As) to consolidate their market positions and expand their product portfolios.

Challenges and Opportunities: Challenges include stringent regulatory frameworks, high treatment costs, and a lack of awareness in underdeveloped regions. Nonetheless, opportunities for market players to innovate and differentiate their offerings are projected to overcome these challenges.

Glaucoma Therapeutics Market Trends/Drivers:

Numerous technological innovation in surgical procedures

The advent of technological innovation in surgical procedures has significantly influenced the global market. One of the most groundbreaking developments is Minimally Invasive Glaucoma Surgeries (MIGS). These surgical interventions have proved to be transformative by causing fewer complications, necessitating shorter recovery periods, and being easier to perform than traditional surgical methods like trabeculectomy. The ease of MIGS has empowered surgeons with more options to manage the disease effectively while minimizing the potential risks and discomfort to the patient. In addition, advancements in surgical medical devices such as micro-stents and new drainage systems have further improved the effectiveness of glaucoma surgeries. These advancements have, in turn, increased the trust among healthcare practitioners and patients across the globe in surgical solutions as viable treatment options for glaucoma.

Rising adoption of telemedicine in ophthalmology

Telemedicine has increasingly become an integral part of healthcare, and its applications in ophthalmology are particularly noteworthy when it comes to the glaucoma therapeutics market. The digitalization of healthcare, coupled with technological advancements in software and hardware, has made remote consultations both practical and effective. Patients can now have their conditions monitored without the need for frequent hospital visits, which is especially beneficial for those residing in rural or remote locations. This wider reach of healthcare services enhances patient engagement, thereby contributing to better outcomes. Remote consultations enable continuous monitoring, and real-time data can alert healthcare providers to changes in a patient's condition that may require immediate intervention. The enhanced data collection capabilities also offer unprecedented opportunities for research, thereby potentially accelerating the development of new treatment modalities.

An enhanced focus on holistic approaches to patient care

An integrated, holistic treatment plan often involves a multi-disciplinary team of healthcare providers, including nutritionists, physiotherapists, and psychological counselors, among others. This not only gives patients a more comprehensive treatment plan but also opens up cross-selling and up-selling opportunities within the healthcare ecosystem. The focus has moved beyond treating the symptoms to a more integrated approach, taking into account patient education, lifestyle changes, and preventive measures alongside medical interventions. A holistic approach also recognizes the role of lifestyle factors such as diet, exercise, and stress management in managing glaucoma. Patients are educated about the types of foods and activities that can help in reducing intraocular pressure, which is a critical factor in glaucoma. This multi-pronged approach not only enhances the effectiveness of medical treatments but also improves the overall quality of life for the patients.

Glaucoma Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global glaucoma therapeutics market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on drug class, indication and end user.

Breakup by Drug Class:

Prostaglandin Analogs

Beta Blockers

Alpha Adrenergic Agonists

Carbonic Anhydrase Inhibitors

Combination Drugs

Others

Prostaglandin analogs represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes prostaglandin analogs, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, combination drugs and others. According to the report, prostaglandin analogs represented the largest segment.

The prostaglandin analogs segment in the market is predominantly driven by their efficacy in reducing intraocular pressure with fewer systemic side effects compared to other classes of glaucoma medications. The once-daily dosing convenience of these drugs also contributes to patient compliance, thereby increasing its market demand. Innovation in formulations and delivery mechanisms is another major factor contributing to its market share. Intellectual property expiry and subsequent entry of generics, however, pose a challenge to market growth. Lastly, their versatile compatibility with other classes of glaucoma medications makes them a preferred choice in combination therapies, bolstering the segment's prominence.

On the other hand, the beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, combination drugs and other segments are influenced by a diverse range of factors such as affordability, varied mechanisms of action, and well-established safety profiles. These drugs are often prescribed in cases where Prostaglandin Analogs are contraindicated or not effective. Despite their efficacy, the need for multiple daily dosing can impact patient compliance. Availability of generics in this category also makes it a cost-effective option for treatment.

Breakup by Indication:

Open Angle Glaucoma

Angle Closure Glaucoma

Others

Open angle glaucoma represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the indication. This includes open angle glaucoma, angle closure glaucoma and others. According to the report, open angle glaucoma represented the largest segment.

The open-angle glaucoma segment is primarily fueled by its prevalence, constituting the majority of glaucoma cases globally. Increased awareness and advancements in diagnostic techniques have led to earlier and more frequent detection of this condition. The availability of multiple treatment options, ranging from medications to surgeries, offers a comprehensive approach to managing open-angle glaucoma. Aging demographics further amplify the incidence rates, thereby driving glaucoma therapeutics market demand. Government initiatives aimed at eye health contribute to the overall market growth for this segment.

On the other hand, the growth in angle closure glaucoma and other segments is primarily driven by an aging population, as the condition is more prevalent among older adults. Advances in diagnostic technologies have also contributed to the segment's expansion by enabling earlier and more accurate detection of the condition. In addition, the increased awareness about the severity of untreated angle-closure glaucoma, which can lead to blindness, has led to higher demand for effective treatments.

Breakup by End User:

Hospitals

Ophthalmic Clinics

Ambulatory Surgery Centers

Others

Hospitals accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, ophthalmic clinics, ambulatory surgery centers and others. According to the report, hospitals represented the largest segment.

Hospitals are major consumers in the glaucoma therapeutics market, given their capability to offer advanced diagnostic and surgical interventions. The consolidation of healthcare facilities and investment in state-of-the-art ophthalmic departments contribute to the segment's growth. Additionally, hospitals are often the first point of contact for emergency eye conditions, thereby positioning them as crucial stakeholders. Public and private insurance coverages also incentivize treatment in hospital settings, increasing patient throughput and consumption of glaucoma medications.

On the other hand, the growth in ophthalmic clinics, ambulatory surgery centers, and other segments can be attributed to the specialized focus on eye care, the availability of advanced diagnostic equipment, and faster patient turnover. Increasing consumer preference for specialized care is also a contributing factor. Decentralization of healthcare services and the expansion of ambulatory surgery centers make these settings accessible for minor procedures and regular check-ups. The growth is further supported by flexible payment options and shorter waiting times.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest glaucoma therapeutics market share

The glaucoma therapeutics market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The market in the North America region is significantly impelled by high healthcare expenditure, robust insurance frameworks, and the presence of leading pharmaceutical companies are primary drivers. Furthermore, the region is home to a diverse and aging population, thereby creating a natural demand for glaucoma treatments. Technological advancements in drug formulation and delivery, backed by substantial investments in research and development, also fuel glaucoma therapeutics market growth.

Regulatory support in terms of expedited approvals and grants fosters innovation, providing a favorable environment for market expansion. Government initiatives in healthcare education and eye screenings contribute to early diagnosis and, in turn, drive demand for therapeutics. Accessibility to specialty ophthalmic clinics and ambulatory surgery centers adds another layer of convenience, encouraging timely intervention.

The availability of both branded and generic drugs offers options across various price points, catering to a wide consumer base. Furthermore, collaborations between public and private sectors in healthcare initiatives serve to increase awareness as well as facilitate entry and acceptance of novel therapeutic solutions in the market.

Competitive Landscape:

The major players in the market are persistently working to develop more effective and less invasive treatment options. They are investing heavily in clinical trials to produce medicines and devices that provide longer-lasting relief with fewer side effects. Collaborations with research institutions and healthcare organizations are common strategies these key players are adopting. Market leaders are also expanding their portfolios by launching innovative products specifically designed to manage different types of glaucoma. Furthermore, these companies are working diligently to meet stringent regulatory requirements, ensuring that their products are both safe and effective. Furthermore, they are also focusing on patient education and awareness programs as a part of their market expansion strategies, thereby offering a favorable glaucoma therapeutics market outlook.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Aerie Pharmaceuticals Inc.

Allergan Plc

Bausch & Lomb Incorporated (Bausch Health Companies Inc.)

Inotek Pharmaceuticals Corp.

Merck & Co. Inc.

Novartis AG

Pfizer Inc.

Santen Pharmaceutical Co. Ltd.

SIFI S.p.A

Teva Pharmaceutical Industries Ltd

Recent Developments:

In November 2022, Aerie Pharmaceuticals, Inc. was acquired by Alcon, the global leader in eye care. Through the transaction, Alcon has added the commercial products Rocklatan(netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa(netarsudil ophthalmic solution) 0.02%, AR-15512, a Phase 3 product candidate for dry eye disease and also a pipeline of ophthalmic pharmaceutical product candidates.

In July 2023, Bausch Health Companies Inc. announced that Bausch Receivables Funding LP, an Ontario limited partnership and wholly-owned subsidiary of Bausch Health, has entered into a $600 million non-recourse financing facility with KKR and its credit funds and accounts. The facility will be collateralized by certain accounts receivables originated by a wholly-owned subsidiary of Bausch Health.

Merck & Co. announced that the European Commission (EC) has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in adults whose tumors express PD-L1 (Combined Positive Score [CPS] >=1).

Key Questions Answered in This Report

  • 1. How big is the global glaucoma therapeutics market?
  • 2. What is the expected growth rate of the global glaucoma therapeutics market during 2024-2032?
  • 3. What are the key factors driving the global glaucoma therapeutics market?
  • 4. What has been the impact of COVID-19 on the global glaucoma therapeutics market?
  • 5. What is the breakup of the global glaucoma therapeutics market based on the drug class?
  • 6. What is the breakup of the global glaucoma therapeutics market based on the indication?
  • 7. What is the breakup of the global glaucoma therapeutics market based on the end user?
  • 8. What are the key regions in the global glaucoma therapeutics market?
  • 9. Who are the key players/companies in the global glaucoma therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Glaucoma Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Prostaglandin Analogs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Beta Blockers
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alpha Adrenergic Agonists
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Carbonic Anhydrase Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Combination Drugs
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Open Angle Glaucoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Angle Closure Glaucoma
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ophthalmic Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ambulatory Surgery Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Aerie Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Allergan Plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Inotek Pharmaceuticals Corp.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Merck & Co. Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Novartis AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Santen Pharmaceutical Co. Ltd.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SIFI S.p.A
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Glaucoma Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Glaucoma Therapeutics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Glaucoma Therapeutics Market: Breakup by Drug Class (in %), 2023
  • Figure 4: Global: Glaucoma Therapeutics Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Glaucoma Therapeutics Market: Breakup by End User (in %), 2023
  • Figure 6: Global: Glaucoma Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Glaucoma Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 8: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Glaucoma Therapeutics (Beta Blockers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Glaucoma Therapeutics (Beta Blockers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Glaucoma Therapeutics (Combination Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Glaucoma Therapeutics (Combination Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Glaucoma Therapeutics (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Glaucoma Therapeutics (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Glaucoma Therapeutics (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Glaucoma Therapeutics (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Glaucoma Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Glaucoma Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Glaucoma Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Glaucoma Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: North America: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: North America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: United States: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: United States: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Canada: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Canada: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Asia Pacific: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Asia Pacific: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: China: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: China: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Japan: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Japan: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: India: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: India: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: South Korea: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: South Korea: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Australia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Australia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Indonesia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Indonesia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Europe: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Europe: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Germany: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Germany: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: France: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: France: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: United Kingdom: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: United Kingdom: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Italy: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Italy: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Spain: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Spain: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Russia: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Russia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Latin America: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Latin America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Brazil: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Brazil: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Mexico: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Mexico: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Others: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Middle East and Africa: Glaucoma Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Middle East and Africa: Glaucoma Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Global: Glaucoma Therapeutics Industry: SWOT Analysis
  • Figure 83: Global: Glaucoma Therapeutics Industry: Value Chain Analysis
  • Figure 84: Global: Glaucoma Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Glaucoma Therapeutics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Glaucoma Therapeutics Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Glaucoma Therapeutics Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 4: Global: Glaucoma Therapeutics Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Glaucoma Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Glaucoma Therapeutics Market: Competitive Structure
  • Table 7: Global: Glaucoma Therapeutics Market: Key Players